National Hospital Organization Nagoya Medical Center, Department of Respiratory Medicine, Nagoya, Japan.
Department of Respiratory Medicine, Nagoya University, Nagoya, Japan.
Thorac Cancer. 2022 Jun;13(12):1783-1787. doi: 10.1111/1759-7714.14454. Epub 2022 May 6.
The safety and efficacy of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients aged 70 years and older has been established. However, few studies have evaluated the safety, usefulness, and significance of EBUS-TBNA in patients aged 80 years and older.
We retrospectively investigated patients aged 80 years and older who underwent EBUS-TBNA under local anesthesia. The study period was 10 years; from November 1, 2010 to October 31, 2020. The primary endpoint was the safety of EBUS-TBNA, which was measured as the incidence of complications associated with the procedure. The secondary endpoints were the overall diagnostic rate, malignant disease diagnosis rate, and malignant disease treatment rate.
A total of 111 patients were enrolled in the study, and the median age was 82 years (range: 80-89 years). The incidence of complications (the primary endpoint) was 5% (5/111) and comprised oversedation in one case, chest pain in one case, hypoxemia in two cases, and arrhythmia in one case. Regarding the secondary endpoints, the diagnostic rate for all patients was 75% (83/111), and the diagnostic rate of malignant disease was 89% (75/84). Of the 75 patients with malignant disease diagnosed with EBUS-TBNA, 61 (81%) received tumor-specific therapy in accordance with their diagnoses.
EBUS-TBNA can be considered safe and effective even in patients aged 80 years and older.
经支气管超声引导针吸活检术（EBUS-TBNA）在 70 岁及以上患者中的安全性和有效性已得到证实。然而，很少有研究评估 80 岁及以上患者行 EBUS-TBNA 的安全性、有用性和意义。
我们回顾性调查了在局部麻醉下接受 EBUS-TBNA 的 80 岁及以上患者。研究期间为 10 年；从 2010 年 11 月 1 日至 2020 年 10 月 31 日。主要终点是 EBUS-TBNA 的安全性，以与该程序相关的并发症发生率来衡量。次要终点是总体诊断率、恶性疾病诊断率和恶性疾病治疗率。
共纳入 111 例患者，中位年龄为 82 岁（范围：80-89 岁）。并发症发生率（主要终点）为 5%（5/111），包括 1 例过度镇静、1 例胸痛、2 例低氧血症和 1 例心律失常。关于次要终点，所有患者的诊断率为 75%（83/111），恶性疾病的诊断率为 89%（75/84）。在 75 例经 EBUS-TBNA 诊断为恶性疾病的患者中，61 例（81%）根据诊断接受了肿瘤特异性治疗。
即使在 80 岁及以上的患者中，EBUS-TBNA 也被认为是安全有效的。
